Alibaba Group Holding Limited (NYSE: BABA) is the largest online and mobile commerce company in the world in terms of gross merchandise volume. The company provides the fundamental technology infrastructure and marketing reach to help businesses leverage the power of the Internet to establish an online presence and conduct commerce with hundreds of millions of consumers and other businesses.

After the company’s stunning IPO on the NYSE earlier this year, the BABA seems to be continuing its financial success. Read the details in the report at the link: http://bit.ly/-BABA--AnalystReport

Northwest Biopharmaceutics, Inc. (NASDAQ: NWBO) is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe.

Get an update on the company’s progress with its cancer treatment platform technology in the report you can read here: http://bit.ly/-NWBO-AnalystReport

Cellceutix, Inc. (OTCBB: CTIX) is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications. The anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial. Cellceutix will soon begin a Phase 2 clinical trial with its Brilacidin-OM for the prevention and treatment of Oral Mucositis. Their anti-psoriasis drug Prurisol has recently completed a Phase 1 clinical trial and is being readied for a Phase 2 trial. Cellceutix's key antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections.

The company has a new COO. Read about his recent comments about company operations in the report that follows: http://bit.ly/-CTIX-AnalystReport

Castle Brands, Inc. (NYSE-MKT: ROX) is a developer and international marketer of premium beverage alcohol brands including: Gosling's Rum, Jefferson's, Jefferson's Presidential Select and Jefferson's Reserve Bourbon, Jefferson's Rye Whiskey, Knappogue Castle Whiskey, Clontarf Irish Whiskey, Pallini Limoncello, Boru Vodka and Brady's Irish Cream, Celtic Honey Liqueur and Castello Mio Sambuca.

The company discussed its financial results for the first quarter of their 2015 fiscal year. Get the report here: http://bit.ly/-ROX-AnalystReport

Special Profile can be viewed by rewading one of the previous reports.

Disclosure: Small Cap Traders has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

The information contained herein is not intended to be investment advice and does not constitute any form of invitation or inducement to engage in investment activity. Neither the information nor any opinion expressed constitutes a solicitation for the purchase or sale of any security. Securities, financial instruments, strategies, or commentary mentioned herein may not be suitable for all investors and this material is not intended for any specific investor and does not take into account an investor’s particular investment objectives, financial situations or needs. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only current as of the stated date of their issue. Prices, values, or income from any securities or investments mentioned in this report may fluctuate, and an investor may, upon selling an investment lose a portion of, or the entire principal amount invested. Past performance is no guarantee of future results. Before acting on any recommendation in this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice.


FORWARD-LOOKING STATEMENT


This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
This report was prepared for informational purposes only. Affiliated parties involved with producing and issuing this report have not been compensated in any form. A full disclaimer can be found by viewing the full analyst report.
 

Innovation Pharmaceuticals (PK) (USOTC:IPIX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Innovation Pharmaceuticals (PK) Charts.
Innovation Pharmaceuticals (PK) (USOTC:IPIX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Innovation Pharmaceuticals (PK) Charts.